Risk of Incident Diabetes Mellitus Associated with the Dosage and Duration of Oral Glucocorticoid Therapy in Patients with Rheumatoid Arthritis

Arthritis and Rheumatology

Volumn 68, Issue 5, 2016, Pages 1089-1098

  Movahedi, Mohammad ^a   Beauchamp, Marie Eve ^b   Abrahamowicz, Michal ^b   Ray, David W ^a   Michaud, Kaleb ^c,d   Pedro, Sofia ^d   Dixon, William G ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NATIONAL DATA BANK FOR RHEUMATIC DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOCORTICOID; HYDROXYCHLOROQUINE; LEFLUNOMIDE; METHOTREXATE; ANTIDIABETIC AGENT; PREDNISOLONE;

ARTICLE; COHORT ANALYSIS; COMORBIDITY; CORTICOSTEROID THERAPY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; INCIDENCE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; UNEMPLOYMENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; DIABETES MELLITUS, TYPE 2; FEMALE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; RISK FACTOR; TIME FACTOR;

ADULT; AGED; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; MIDDLE AGED; PREDNISOLONE; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK; RISK FACTORS; TIME FACTORS;

EID: 84964613627     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39537     Document Type: Article

References (38)

1. Caplan L, Wolfe F, Russell AS, Michaud K., Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. J Rheumatol 2007; 34: 696-705.
2. Gotzsche PC, Johansen HK., Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998; 316: 811-8.
3. Kirwan JR, Bijlsma JW, Boers M, Shea BJ., Effects of glucocorticoids on radiological progression in rheumatoid arthritis. Cochrane Database Syst Rev 2007: CD006356.
4. Hoes JN, Jacobs JW, Buttgereit F, Bijlsma JW., Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat Rev Rheumatol 2010; 6: 693-702.
5. Saag KG., Short-term and long-term safety of glucocorticoids in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2012; 70 Suppl 1: 21-5.
6. Di Dalmazi G, Pagotto U, Pasquali R, Vicennati V., Glucocorticoids and type 2 diabetes: from physiology to pathology. J Nutr Metab 2012; 2012: 525093.
7. Dessein PH, Joffe BI, Stanwix AE, Christian BF, Veller M., Glucocorticoids and insulin sensitivity in rheumatoid arthritis. J Rheumatol 2004; 31: 867-74.
8. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al., Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298: 187-93.
9. Di Comite G, Rossi CM., Risk of diabetes in patients with rheumatoid arthritis taking hydroxychloroquine. JAMA 2007; 298: 2368-9.
10. Abrahamowicz M, Beauchamp ME, Sylvestre MP., Comparison of alternative models for linking drug exposure with adverse effects. Stat Med 2012; 31: 1014-30.
11. Dixon WG, Abrahamowicz M, Beauchamp ME, Ray DW, Bernatsky S, Suissa S, et al., Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 2012; 71: 1128-33.
12. Sylvestre MP, Abrahamowicz M., Flexible modeling of the cumulative effects of time-dependent exposures on the hazard. Stat Med 2009; 28: 3437-53.
13. Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ., Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 2010; 69: 4-14.
14. Thomas SL, Edwards CJ, Smeeth L, Cooper C, Hall AJ., How accurate are diagnoses for rheumatoid arthritis and juvenile idiopathic arthritis in the General Practice Research Database? Arthritis Rheum 2008; 59: 1314-21.
15. Wolfe F, Michaud K., The National Data Bank for rheumatic diseases: a multi-registry rheumatic disease data bank. Rheumatology (Oxford) 2011; 50: 16-24.
16. Rubin DB., Multiple imputation for non-response in surveys. New York: John Wiley & Sons; 1987.
17. Van Buuren S, Boshuizen HC, Knook DL., Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999; 18: 681-94.
18. Michaud K, Wolfe F., Comorbidities in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2007; 21: 885-906.
19. Fries JF, Spitz P, Kraines RG, Holman HR., Measurement of patient outcome in arthritis. Arthritis Rheum 1980; 23: 137-45.
20. Cox D., Regression models and life-tables. JR Stat Soc Ser B 1972; 34: 187-220.
21. Suissa S., Calculation of number needed to treat. N Engl J Med 2009; 361: 424-5.
22. Akaike H., A new look at the statistical model identification. IEEE Trans Automat Contr 1974; 19: 716-23.
23. Quantin C, Abrahamowicz M, Moreau T, Bartlett G, MacKenzie T, Tazi MA, et al., Variation over time of the effects of prognostic factors in a population-based study of colon cancer: comparison of statistical models. Am J Epidemiol 1999; 150: 1188-200.
24. Solomon DH, Love TJ, Canning C, Schneeweiss S., Risk of diabetes among patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. Ann Rheum Dis 2010; 69: 2114-7.
25. Hoes JN, van der Goes MC, van Raalte DH, van der Zijl NJ, den Uyl D, Lems WF, et al., Glucose tolerance, insulin sensitivity and β-cell function in patients with rheumatoid arthritis treated with or without low-to-medium dose glucocorticoids. Ann Rheum Dis 2011; 70: 1887-94.
26. Den Uyl D, van Raalte DH, Nurmohamed MT, Lems WF, Bijlsma JW, Hoes JN, et al., Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum 2012; 64: 639-46.
27. Abrahamowicz M, Xiao Y, Ionescu-Ittu R, Lacaille D., Simulations showed that validation of database-derived diagnostic criteria based on a small subsample reduced bias. J Clin Epidemiol 2007; 60: 600-9.
28. Bili A, Sartorius JA, Kirchner HL, Morris SJ, Ledwich LJ, Antohe JL, et al., Hydroxychloroquine use and decreased risk of diabetes in rheumatoid arthritis patients. J Clin Rheumatol 2011; 17: 115-20.
29. Solomon DH, Massarotti E, Garg R, Liu J, Canning C, Schneeweiss S., Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA 2011; 305: 2525-31.
30. Powrie JK, Smith GD, Shojaee-Moradie F, Sonksen PH, Jones RH., Mode of action of chloroquine in patients with non-insulin-dependent diabetes mellitus. Am J Physiol 1991; 260: E897-904.
31. Wolfe F, Flowers N, Burke TA, Arguelles LM, Pettitt D., Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 1015-22.
32. Penesova A, Radikova Z, Vlcek M, Kerlik J, Lukac J, Rovensky J, et al., Chronic inflammation and low-dose glucocorticoid effects on glucose metabolism in premenopausal females with rheumatoid arthritis free of conventional metabolic risk factors. Physiol Res 2013; 62: 75-83.
33. Dessein PH, Joffe BI., Insulin resistance and impaired beta cell function in rheumatoid arthritis. Arthritis Rheum 2006; 54: 2765-75.
34. Giles JT, Danielides S, Szklo M, Post WS, Blumenthal RS, Petri M, et al., Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol 2015; 67: 626-36.
35. Seriolo B, Ferrone C, Cutolo M., Longterm anti-tumor necrosis factor-α treatment in patients with refractory rheumatoid arthritis: relationship between insulin resistance and disease activity. J Rheumatol 2008; 35: 355-7.
36. Shahin D, Eltoraby E, Mesbah A, Houssen M., Insulin resistance in early untreated rheumatoid arthritis patients. Clin Biochem 2010; 43: 661-5.
37. Dubreuil M, Rho YH, Man A, Zhu Y, Zhang Y, Love TJ, et al., Diabetes incidence in psoriatic arthritis, psoriasis and rheumatoid arthritis: a UK population-based cohort study. Rheumatology (Oxford) 2014; 53: 346-52.
38. Hoes JN, Jacobs JW, Boers M, Boumpas D, Buttgereit F, Caeyers N, et al., EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2007; 66: 1560-7.